Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Central autonomic network dysfunction and plasma Alzheimer's disease biomarkers in older adults.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101511643 Publication Model: Electronic Cited Medium: Internet ISSN: 1758-9193 (Electronic) NLM ISO Abbreviation: Alzheimers Res Ther Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: [London] : BioMed Central Ltd.
    • الموضوع:
      Alzheimer Disease*/blood ; Alzheimer Disease*/physiopathology ; Alzheimer Disease*/diagnostic imaging ; Biomarkers*/blood ; Amyloid beta-Peptides*/blood ; Magnetic Resonance Imaging*; Humans ; Female ; Aged ; Male ; Brain/diagnostic imaging ; Brain/physiopathology ; Peptide Fragments/blood ; Autonomic Nervous System/physiopathology ; Glial Fibrillary Acidic Protein/blood ; Aged, 80 and over ; Neurofilament Proteins/blood ; Autonomic Nervous System Diseases/blood ; Autonomic Nervous System Diseases/physiopathology ; Autonomic Nervous System Diseases/etiology
    • نبذة مختصرة :
      Background: Higher order regulation of autonomic function is maintained by the coordinated activity of specific cortical and subcortical brain regions, collectively referred to as the central autonomic network (CAN). Autonomic changes are frequently observed in Alzheimer's disease (AD) and dementia, but no studies to date have investigated whether plasma AD biomarkers are associated with CAN functional connectivity changes in at risk older adults.
      Methods: Independently living older adults (N = 122) without major neurological or psychiatric disorder were recruited from the community. Participants underwent resting-state brain fMRI and a CAN network derived from a voxel-based meta-analysis was applied for overall, sympathetic, and parasympathetic CAN connectivity using the CONN Functional Toolbox. Sensorimotor network connectivity was studied as a negative control. Plasma levels of amyloid (Aβ 42 , Aβ 40 ), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were assessed using digital immunoassay. The relationship between plasma AD biomarkers and within-network functional connectivity was studied using multiple linear regression adjusted for demographic covariates and Apolipoprotein E (APOE) genotype. Interactive effects with APOE4 carrier status were also assessed.
      Results: All autonomic networks were positively associated with Aβ 42/40 ratio and remained so after adjustment for age, sex, and APOE4 carrier status. Overall and parasympathetic networks were negatively associated with GFAP. The relationship between the parasympathetic CAN and GFAP was moderated by APOE4 carrier status, wherein APOE4 carriers with low parasympathetic CAN connectivity displayed the highest plasma GFAP concentrations (B = 910.00, P = .004). Sensorimotor connectivity was not associated with any plasma AD biomarkers, as expected.
      Conclusion: The present study findings suggest that CAN function is associated with plasma AD biomarker levels. Specifically, lower CAN functional connectivity is associated with decreased plasma Aβ 42/40 , indicative of cerebral amyloidosis, and increased plasma GFAP in APOE4 carriers at risk for AD. These findings could suggest higher order autonomic and parasympathetic dysfunction in very early-stage AD, which may have clinical implications.
      (© 2024. The Author(s).)
    • References:
      Acta Neuropathol. 1991;82(4):239-59. (PMID: 1759558)
      Medicina (Kaunas). 2020 Jul 08;56(7):. (PMID: 32650427)
      PLoS One. 2013 Apr 23;8(4):e62101. (PMID: 23626774)
      Neurology. 2022 Jun 14;98(24):e2446-e2453. (PMID: 35418462)
      Am J Physiol. 1987 Sep;253(3 Pt 2):H680-9. (PMID: 3631301)
      Mayo Clin Proc. 1993 Oct;68(10):988-1001. (PMID: 8412366)
      J Inflamm Res. 2021 Dec 30;14:7501-7506. (PMID: 35002283)
      Sci Rep. 2023 Mar 9;13(1):3967. (PMID: 36894565)
      Med Hypotheses. 2006;67(4):747-58. (PMID: 16806725)
      Biol Psychiatry. 2010 Mar 15;67(6):584-7. (PMID: 19833321)
      Nat Rev Neurol. 2022 Mar;18(3):158-172. (PMID: 35115728)
      Front Aging Neurosci. 2021 Sep 28;13:711784. (PMID: 34650423)
      Brain Connect. 2014 Jun;4(5):299-311. (PMID: 24796856)
      Neuroimage. 2006 Jun;31(2):496-504. (PMID: 16473024)
      Hypertension. 2019 Nov;74(5):1172-1180. (PMID: 31542965)
      Arch Neurol. 2007 Oct;64(10):1482-7. (PMID: 17923631)
      Alzheimers Res Ther. 2018 Jul 28;10(1):71. (PMID: 30055655)
      J Neurosci. 2013 Jun 19;33(25):10503-11. (PMID: 23785162)
      Brain. 2021 Dec 16;144(11):3505-3516. (PMID: 34259835)
      Brain Struct Funct. 2020 Jun;225(5):1575-1585. (PMID: 32350644)
      Neurology. 2021 Sep 20;97(12):e1229-e1242. (PMID: 34266917)
      Am J Physiol Regul Integr Comp Physiol. 2002 Oct;283(4):R815-26. (PMID: 12228049)
      Cells. 2023 May 04;12(9):. (PMID: 37174709)
      Alzheimers Dement. 2023 Jul;19(7):2790-2804. (PMID: 36576155)
      Neurosci Biobehav Rev. 2022 Dec;143:104907. (PMID: 36243195)
      J Neurol. 2022 Aug;269(8):4270-4280. (PMID: 35288777)
      JAMA Neurol. 2021 Dec 1;78(12):1471-1483. (PMID: 34661615)
      Genome Biol. 2019 Jun 4;20(1):118. (PMID: 31164141)
      J Alzheimers Dis. 2015;47(3):681-9. (PMID: 26401703)
      Brain Connect. 2012;2(3):125-41. (PMID: 22642651)
      Lancet. 1998 Feb 14;351(9101):478-84. (PMID: 9482439)
      Neuroimage Clin. 2019;23:101860. (PMID: 31158694)
      J Neuropathol Exp Neurol. 2011 Nov;70(11):960-9. (PMID: 22002422)
      Dement Neuropsychol. 2008 Jul-Sep;2(3):183-191. (PMID: 29213568)
      Brain Sci. 2023 Sep 14;13(9):. (PMID: 37759923)
      Alzheimers Dement. 2008 Jul;4(4):265-70. (PMID: 18631977)
      J Alzheimers Dis. 2021;83(1):65-75. (PMID: 34250941)
      J Alzheimers Dis. 2011;25(2):309-21. (PMID: 21422523)
      Geriatr Gerontol Int. 2017 Jan;17(1):92-98. (PMID: 26643357)
      Ann Neurol. 2021 Sep;90(3):391-406. (PMID: 34279043)
      Neurobiol Aging. 2012 Oct;33(10):2324-33. (PMID: 22188719)
      Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4637-42. (PMID: 15070770)
      Neuroimage. 2019 Aug 15;197:383-390. (PMID: 31055043)
      J Am Heart Assoc. 2024 May 7;13(9):e034116. (PMID: 38686898)
    • Grant Information:
      DFD-170763 Canada CIHR; K24AG081325 United States NH NIH HHS; P30AG066519 United States NH NIH HHS; R01AG064228 United States NH NIH HHS; R01 AG060049 United States AG NIA NIH HHS; R01 AG082073 United States AG NIA NIH HHS; P01 AG052350 United States AG NIA NIH HHS; P30 AG066530 United States AG NIA NIH HHS
    • Contributed Indexing:
      Keywords: Alzheimer’s Disease; Aβ42/40; Central autonomic network; Glial fibrillary acidic protein; Neurofilament light chain
    • الرقم المعرف:
      0 (Biomarkers)
      0 (Amyloid beta-Peptides)
      0 (Peptide Fragments)
      0 (amyloid beta-protein (1-42))
      0 (Glial Fibrillary Acidic Protein)
      0 (Neurofilament Proteins)
      0 (amyloid beta-protein (1-40))
      0 (neurofilament protein L)
    • الموضوع:
      Date Created: 20240608 Date Completed: 20240608 Latest Revision: 20240712
    • الموضوع:
      20240713
    • الرقم المعرف:
      PMC11162037
    • الرقم المعرف:
      10.1186/s13195-024-01486-9
    • الرقم المعرف:
      38851772